- Home
- ATHA vs SISI Comparison
ATHA vs SISI Comparison
Compare ATHA & SISI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- SISI
- Stock Information
- Founded
- ATHA 2011
- SISI 1997
- Country
- ATHA United States
- SISI China
- Employees
- ATHA N/A
- SISI N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- SISI Medicinal Chemicals and Botanical Products
- Sector
- ATHA Health Care
- SISI Health Care
- Exchange
- ATHA Nasdaq
- SISI Nasdaq
- Market Cap
- ATHA 21.0M
- SISI 17.9M
- IPO Year
- ATHA 2020
- SISI 2016
- Fundamental
- Price
- ATHA $0.27
- SISI $0.88
- Analyst Decision
- ATHA Buy
- SISI
- Analyst Count
- ATHA 4
- SISI 0
- Target Price
- ATHA $11.25
- SISI N/A
- AVG Volume (30 Days)
- ATHA 209.7K
- SISI 128.8K
- Earning Date
- ATHA 05-14-2025
- SISI 05-14-2025
- Dividend Yield
- ATHA N/A
- SISI N/A
- EPS Growth
- ATHA N/A
- SISI N/A
- EPS
- ATHA N/A
- SISI N/A
- Revenue
- ATHA N/A
- SISI $11,072,553.00
- Revenue This Year
- ATHA N/A
- SISI N/A
- Revenue Next Year
- ATHA N/A
- SISI N/A
- P/E Ratio
- ATHA N/A
- SISI N/A
- Revenue Growth
- ATHA N/A
- SISI 145.88
- 52 Week Low
- ATHA $0.25
- SISI $0.73
- 52 Week High
- ATHA $3.67
- SISI $117.65
- Technical
- Relative Strength Index (RSI)
- ATHA 29.05
- SISI 42.72
- Support Level
- ATHA $0.25
- SISI $0.85
- Resistance Level
- ATHA $0.31
- SISI $1.27
- Average True Range (ATR)
- ATHA 0.03
- SISI 0.15
- MACD
- ATHA -0.00
- SISI 0.01
- Stochastic Oscillator
- ATHA 12.38
- SISI 22.37
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.